CFRX
|ContraFect Corp
NASDAQ
USD
|%
Current Price
Change
(%)
P/E Ratio
Dividend Yield
Market Cap
535,240
Volume
Open
Previous Close
52-Week High
52-Week Low
About ContraFect Corp
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudo...
Sector:Healthcare
Industry:Biotechnology
CEO:Dr. Roger James Pomerantz F.A.C.P., FACP, M.D.
Employees:23
Headquarters:Yonkers, USA
Website:www.contrafect.com
Dividend History
Dividend Payments
| Declared Date | Record Date | Payment Date | Amount | Frequency |
|---|
Similar Companies
Explore Stocks by Sector
technology
finance
healthcare
Frequently Asked Questions